ArticlePediatric nephrology (Berlin, Germany)2011
Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity.
Article in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Clinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication.Clinical and experimental nephrology · 2026Review
- Machine learning differentiation of abdominal IgA vasculitis without purpura from appendicitis.Pediatric research · 2026Article
- Article
- Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis.Pediatric nephrology (Berlin, Germany) · 2023Article
- Immunoglobulin A vasculitis nephritis: Current understanding of pathogenesis and treatment.World journal of nephrology · 2023Review
- A simple nomogram for assessing the risk of IgA vasculitis nephritis in IgA vasculitis Asian pediatric patients.Scientific reports · 2022Article
- Early clinical course of biopsy-proven IgA vasculitis nephritis.BMC pediatrics · 2022Article
- Mycophenolate Mofetil for Severe IgA Vasculitis Nephropathy in Children: An Observational Study.Kidney medicine · 2022Article
- Use of renin-angiotensin system inhibitors as initial therapy in children with Henoch-Schönlein purpura nephritis of moderate severity.Pediatric nephrology (Berlin, Germany) · 2022Article
- To biopsy or not to biopsy: Henoch-Schönlein nephritis in children, a 5-year follow-up study.Pediatric nephrology (Berlin, Germany) · 2022Article
- Management of IgA Vasculitis with Nephritis.Paediatric drugs · 2021Review
- Efficacy and safety of low-dose corticosteroid with azathioprine in the treatment of elderly-onset IgA vasculitis with nephritis.BMJ case reports · 2021Article
- Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study.Pediatric nephrology (Berlin, Germany) · 2019Article
- Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents.Pediatric nephrology (Berlin, Germany) · 2017Article
- Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases.Pediatric rheumatology online journal · 2016Article
- Beneficial effects of creatine phosphate sodium for the treatment of Henoch-Schönlein purpura in patients with early renal damage detected using urinary kidney injury molecule-1 levels.European journal of pediatrics · 2016Article
- Henoch-Schönlein purpura nephritis in children.Nature reviews. Nephrology · 2014Review
- Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis.Pediatric nephrology (Berlin, Germany) · 2013Article
- Henoch-Schönlein purpura with hypocomplementemia.Pediatric nephrology (Berlin, Germany) · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of Henoch-Schönlein purpura nephritis (HSPN) is controversial. It has been revealed that some patients develop end-stage renal disease and aggressive treatment with drugs such as steroids is increasing, and some of them may be overzealous. At our institutes, our treatment decisions are based on the clinical and pathological severity of the case in an attempt to limit the indications for aggressive therapies such as steroids and immunosuppressive agents. Here, we retrospectively examined the efficacy of treatment for HSPN. Renal biopsy was performed in patients with nephrotic syndrome or persistent proteinuria for more than 3 months and patients were classified by treatment. Patients (n=31) with moderately severe HSPN (histological grade I-III and serum albumin [Alb] >2.5 g/dl) were treated with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers. Patients (n=19) with HSPN exceeding grade III or Alb ≤ 2.5 g/dl received combination therapy comprising prednisolone, immunosuppressants, warfarin, and dipyridamole. All patients showed resolution of proteinuria without renal dysfunction during the observation period (3.76 ± 0.37 years). Our findings support those of some earlier reports that treatment strategies for HSPN should depend on the histological and clinical severity. Furthermore, aggressive therapies, particularly combination therapies, are unnecessary for moderate-severe HSPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.